Market Overview

Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Third Quarter Results


Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it
will host a webcast and conference call on August 7, 2018, at 4:30 p.m.
EDT to discuss its financial results for the fiscal 2018 third quarter
ended June 30, 2018.

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at
For analysts that wish to participate in the conference call, please
dial 855-215-6159 or 315-625-6887 and provide Conference ID 8452059.

A replay of the webcast will be available on the company's website
approximately two hours after the conclusion of the call and will remain
available for 90 days. An audio replay will also be available
approximately two hours after the conclusion of the call and will be
available for 3 days. To access the audio replay, dial 855-859-2056 or
404-537-3406 and provide Conference ID 8452059.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable
diseases by silencing the genes that cause them. Using a broad portfolio
of RNA chemistries and efficient modes of delivery, Arrowhead therapies
trigger the RNA interference mechanism to induce rapid, deep, and
durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein.
Arrowhead's RNAi-based therapeutics leverage this natural pathway of
gene silencing.

For more information, please visit,
or follow us on Twitter @ArrowheadPharma.
To be added to the Company's email list and receive news directly,
please visit

Safe Harbor Statement under the Private Securities Litigation Reform

This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the safety and efficacy of our product
candidates, the duration and impact of regulatory delays in our clinical
programs, our ability to finance our operations, the future success of
our scientific studies, our ability to successfully develop drug
candidates, the timing for starting and completing clinical trials,
rapid technological change in our markets, and the enforcement of our
intellectual property rights. Our most recent Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q discuss some of the
important risk factors that may affect our business, results of
operations and financial condition. We assume no obligation to update or
revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

View Comments and Join the Discussion!